NCT07310316 Efficacy and Safety of Variceal Embolization Combined With Partial Splenic Artery Embolization for Variceal Bleeding in Cavernous Transformation of Portal Vein.
| NCT ID | NCT07310316 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Air Force Military Medical University, China |
| Condition | Cavernous Transformation of Portal Vein |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2026-01-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The management of variceal bleeding in patients with cavernous transformation of portal vein (CTPV) generally adheres to the principles applied to cirrhotic portal hypertension, including pharmacological therapy, endoscopic intervention, transjugular intrahepatic portosystemic shunt (TIPS), and surgery. However, the distinct hemodynamic profile caused by portal vein occlusion in CTPV introduces specific therapeutic challenges: 1. Conventional pharmacological and endoscopic treatments often yield suboptimal outcomes. 2. Splenectomy with periesophagogastric devascularization is associated with significant complication rates and elevated perioperative mortality. 3. The feasibility of TIPS depends on sufficient portal venous inflow to ensure stent patency, while also carrying a risk of hepatic encephalopathy. Based on these considerations, the investigators hypothesize that for patients with extensive portal thrombosis and inadequate portal inflow who are ineligible for TIPS, a combination of variceal embolization and partial splenic artery embolization may reduce portal pressure and decrease the risk of esophagogastric variceal bleeding. To evaluate this hypothesis, a retrospective cohort study has been designed.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years; 2. Diagnosis of cavernous transformation of the portal vein (CTPV) confirmed by at least one imaging modality (ultrasonography, CT, or MRI); 3. Portal vein thrombosis (PVT) extending to the splenic vein (SV) and superior mesenteric vein (SMV); 4. History of portal hypertension complicated by variceal bleeding, with recurrent bleeding despite pharmacological and endoscopic therapies; 5. Treated with combined variceal embolization and partial splenic artery embolization; 6. Availability of at least one postoperative follow-up examination with documented clinical data and survival status. Exclusion Criteria: 1. Concomitant malignant tumor; 2. Active infection
Contact & Investigator
Jun Tie
PRINCIPAL INVESTIGATOR
Air Force Military Medical University, China
Frequently Asked Questions
Who can join the NCT07310316 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cavernous Transformation of Portal Vein. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07310316 currently recruiting?
Yes, NCT07310316 is actively recruiting participants. Contact the research team at tiejun7776@163.com for enrollment information.
Where is the NCT07310316 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT07310316 clinical trial?
NCT07310316 is sponsored by Air Force Military Medical University, China. The principal investigator is Jun Tie at Air Force Military Medical University, China. The trial plans to enroll 26 participants.